My PCR
Create Account
Logo PCR

20 May 2026

Stents, scaffolds and DCB

DCB: does coating morphology matter for distal embolisation and clinical outcomes?

Sponsored by Cardionovum

Anchorperson: D. Dudek
Spokesperson: B. Cortese
SHOW MORE

Summary

Drug-coated balloon (DCB) therapy continues to evolve, with increasing attention on how coating design may influence drug transfer, vessel response and downstream clinical outcomes.

This EuroPCR 2026 session examines the role of coating morphology, comparing amorphous and crystalline technologies and their implications for drug delivery efficiency and particle loss. Pre-clinical and animal data are used to illustrate how coating characteristics may affect vascular response and distal embolisation.

Clinical relevance is explored through its potential impact on coronary microcirculation and patient outcomes, supported by evidence from the HYPER programme and long-term results from RESTORE SVD.

Case-based discussion, including blended DES–DCB strategies, provides practical insight into how these differences may translate into everyday interventional decision-making.

Learning Objectives

  • To understand why coating type matters - Discover the practical differences between amorphous and crystalline DCB and how they affect drug delivery and embolisation
  • To see what really happens after inflation - Learn about particle loss and vessel response from pre-clinical and animal studies
  • To understand the impact on the microcirculation - Explore how distal embolisation can influence coronary flow and patient outcomes
  • To apply the evidence in your daily practice - Review key clinical data on amorphous DCB, including the HYPER programme and five-year results from RESTORE SVD, and take-home clear, practical messages
Related Content
The next frontier of DCB is to simplify complexity ISR: sirolimus balloon vs DES or standard PCI A novel bailout technique for the percutaneous extraction of an entrapped coronary guidewire beneath a crushed stent
Recommended for you
1-year SELUTION DeNovo results: DEB strategy vs. systematic DES in de novo coronary disease OCVC-BIF: DCB vs. conventional PTCA for treatment of bifurcation lesion side-branches PCRonline @ TCT 2025 - The international perspective